健康成人完成两剂灭活疫苗后接种减少剂量与标准剂量mRNA COVID-19疫苗加强针的反应原性与免疫原性比较
研究比较了先前接种两剂CoronaVac疫苗的健康成人中,减少剂量与标准剂量BNT162b2和mRNA-1273第三针加强针的反应原性和免疫原性。结果显示,15 μg BNT162b2组头痛、关节痛和腹泻比30 μg组更频繁,100 μg mRNA-1273组关节痛和寒战比50 μg组更频繁;免疫原性无显著差异。减少剂量mRNA疫苗诱导的针对SARS-CoV-2 delta和omicron变异株的抗体反应与标准剂量相当,可在全球疫苗供应有限时用于提高疫苗覆盖率。
要点
- 15 μg BNT162b2组头痛、关节痛和腹泻比30 μg组更频繁。
- 100 μg mRNA-1273组关节痛和寒战比50 μg组更频繁。
- 减少剂量与标准剂量mRNA疫苗加强针的免疫原性无显著差异。
核心结论
- 减少剂量mRNA疫苗诱导的针对SARS-CoV-2 delta和omicron变异株的抗体反应与标准剂量相当。
- 在全球疫苗供应有限的情况下,减少剂量可用于提高疫苗覆盖率。
研究设计与样本
- 研究比较了先前接种两剂CoronaVac疫苗的成人中,减少剂量与标准剂量BNT162b2和mRNA-1273第三针加强针的反应原性和免疫原性。
主要发现
- 头痛、关节痛和腹泻在15 μg BNT162b2组比30 μg BNT162b2组更频繁。
- 关节痛和寒战在100 μg mRNA-1273组比50 μg mRNA-1273组更频繁。
- 减少剂量与标准剂量mRNA疫苗之间的免疫原性无显著差异。
临床怎么用
- 减少剂量mRNA疫苗可在全球疫苗供应有限的情况下用于提高疫苗覆盖率。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The coronavirus disease 2019 (COVID-19) pandemic has been a serious healthcare problem worldwide since December 2019. The third dose of heterologous vaccine was recently approved by World Health Organization. The present study compared the reactogenicity and immunogenicity of the reduced and standard third booster dose of the BNT162b2 and mRNA-1273 vaccine in adults who previously received the two-dose CoronaVac vaccine. Results showed that headache, joint pain, and diarrhea were more frequent in the 15 μg- than the 30 μg-BNT162b2 groups, whereas joint pain and chilling were more frequent in the 100 μg- than the 50 μg-mRNA-1273 groups. No significant differences in immunogenicity were detected. These findings demonstrate that the reduced dose of the mRNA vaccines elicited antibody responses against the SARS-CoV-2 delta and omicron variants that were comparable to the standard dose. The reduced dose could be used to increase vaccine coverage in situations of limited global vaccine supply.
引用
- Kanokudom S, Assawakosri S, Suntronwong N, et al. Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine. Vaccine. 2022. PMID: 36031500. doi:10.1016/j.vaccine.2022.08.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。